Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study. 2005

Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
Department of Pharmacology, State University of Campinas, P.O. Box 6111, Campinas, SP, Brazil.

A rapid, sensitive and specific method to quantify carvedilol in human plasma using metoprolol as the internal standard (IS) is described. The analyte and the IS were extracted from plasma by liquid-liquid extraction using a diethyl-ether solvent. After removed and dried the organic phase, the extracts were reconstituted with a fixed volume of acetonitrile-water (50/50; v/v). The extracts were analyzed by a high performance liquid chromatography coupled to electrospray tandem mass spectrometry (HPLC-MS/MS). Chromatography was performed isocratically on Alltech Prevail C18 5 microm analytical column, (150 mm x 4.6 mm i.d.). The method had a chromatographic run time of 3.5 min and a linear calibration curve over the range 0.1-200 ng ml(-1) (r2>0.997992). The limit of quantification was 0.1 ng ml(-1). This HPLC-MS/MS procedure was used to assess the bioequivalence of two carvedilol 25 mg tablet formulations (carvedilol test formulation from Laboratórios Biosintética Ltda and Coreg from Roche Químicos e Farmacêuticos S.A standard reference formulation). A single 25 mg dose of each formulation was administered to healthy volunteers. The study was conducted using an open, randomized, two-period crossover design with a 2-week wash-out interval. Since the 90% CI for C(max) and AUCs ratios were all inside the 80-125% interval proposed by the US Food and Drug Administration Agency, it was concluded that carvedilol formulation elaborated by Laboratórios Biosintética Ltda is bioequivalent to Coreg formulation for both the rate and the extent of absorption.

UI MeSH Term Description Entries
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D002227 Carbazoles Benzo-indoles similar to CARBOLINES which are pyrido-indoles. In plants, carbazoles are derived from indole and form some of the INDOLE ALKALOIDS.
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077261 Carvedilol A carbazole and propanol derivative that acts as a non-cardioselective beta blocker and vasodilator. It has blocking activity for ALPHA 1 ADRENERGIC RECEPTORS and, at higher doses, may function as a blocker of CALCIUM CHANNELS; it also has antioxidant properties. Carvedilol is used in the treatment of HYPERTENSION; ANGINA PECTORIS; and HEART FAILURE. It can also reduce the risk of death following MYOCARDIAL INFARCTION. BM 14190,BM-14190,Carvedilol Hydrochloride,Carvedilol, (+),Carvedilol, (+)-isomer,Carvedilol, (+-)-isomer,Carvedilol, (-),Carvedilol, (-)-isomer,Carvedilol, (R)-isomer,Carvedilol, (S)-isomer,Carvedilol, 14C-labeled,Coreg,Coropres,Dilatrend,Eucardic,Kredex,Querto,14C-labeled Carvedilol,BM14190,Carvedilol, 14C labeled
D000319 Adrenergic beta-Antagonists Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. Adrenergic beta-Antagonist,Adrenergic beta-Receptor Blockader,Adrenergic beta-Receptor Blockaders,beta-Adrenergic Antagonist,beta-Adrenergic Blocker,beta-Adrenergic Blocking Agent,beta-Adrenergic Blocking Agents,beta-Adrenergic Receptor Blockader,beta-Adrenergic Receptor Blockaders,beta-Adrenoceptor Antagonist,beta-Blockers, Adrenergic,beta-Adrenergic Antagonists,beta-Adrenergic Blockers,beta-Adrenoceptor Antagonists,Adrenergic beta Antagonist,Adrenergic beta Antagonists,Adrenergic beta Receptor Blockader,Adrenergic beta Receptor Blockaders,Adrenergic beta-Blockers,Agent, beta-Adrenergic Blocking,Agents, beta-Adrenergic Blocking,Antagonist, beta-Adrenergic,Antagonist, beta-Adrenoceptor,Antagonists, beta-Adrenergic,Antagonists, beta-Adrenoceptor,Blockader, Adrenergic beta-Receptor,Blockader, beta-Adrenergic Receptor,Blockaders, Adrenergic beta-Receptor,Blockaders, beta-Adrenergic Receptor,Blocker, beta-Adrenergic,Blockers, beta-Adrenergic,Blocking Agent, beta-Adrenergic,Blocking Agents, beta-Adrenergic,Receptor Blockader, beta-Adrenergic,Receptor Blockaders, beta-Adrenergic,beta Adrenergic Antagonist,beta Adrenergic Antagonists,beta Adrenergic Blocker,beta Adrenergic Blockers,beta Adrenergic Blocking Agent,beta Adrenergic Blocking Agents,beta Adrenergic Receptor Blockader,beta Adrenergic Receptor Blockaders,beta Adrenoceptor Antagonist,beta Adrenoceptor Antagonists,beta Blockers, Adrenergic,beta-Antagonist, Adrenergic,beta-Antagonists, Adrenergic,beta-Receptor Blockader, Adrenergic,beta-Receptor Blockaders, Adrenergic
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D013810 Therapeutic Equivalency The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease. Bioequivalence,Clinical Equivalency,Equivalency, Therapeutic,Generic Equivalency,Clinical Equivalencies,Equivalencies, Clinical,Equivalencies, Therapeutic,Equivalency, Clinical,Therapeutic Equivalencies,Bioequivalences,Equivalencies, Generic,Equivalency, Generic,Generic Equivalencies
D021241 Spectrometry, Mass, Electrospray Ionization A mass spectrometry technique used for analysis of nonvolatile compounds such as proteins and macromolecules. The technique involves preparing electrically charged droplets from analyte molecules dissolved in solvent. The electrically charged droplets enter a vacuum chamber where the solvent is evaporated. Evaporation of solvent reduces the droplet size, thereby increasing the coulombic repulsion within the droplet. As the charged droplets get smaller, the excess charge within them causes them to disintegrate and release analyte molecules. The volatilized analyte molecules are then analyzed by mass spectrometry. ESI Mass Spectrometry,Electrospray Ionization Mass Spectrometry,Mass Spectrometry, ESI,Spectrometry, ESI Mass

Related Publications

Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
February 2001, Journal of mass spectrometry : JMS,
Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
April 2002, Journal of mass spectrometry : JMS,
Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
December 2001, Therapeutic drug monitoring,
Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
October 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
March 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
January 2012, Biomedical chromatography : BMC,
Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
June 2018, International journal of clinical pharmacology and therapeutics,
Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
January 2007, Journal of mass spectrometry : JMS,
Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
July 2008, Journal of chromatographic science,
Ney Carter do Carmo Borges, and Gustavo Duarte Mendes, and Diogo de Oliveira Silva, and Vinicius Marcondes Rezende, and Rafael Eliseo Barrientos-Astigarraga, and Gilberto De Nucci
January 2011, Arzneimittel-Forschung,
Copied contents to your clipboard!